Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Viatris.

In this second podcast episode of a 4-part series, haematologists continue to explore different clinical scenarios and challenges in managing thrombosis.

In this conversation, they discuss how to treat thrombosis in patients with cancer, covering:

 

  • When and how to use heparins and/or direct oral anticoagulants (DOACs)

  • The benefits of primary thromboprophylaxis and its efficacy in various tumour types

  • How the patient's involvement could result in an improved quality of life

 

E-learning

After listening to the podcast series, take the e-learning assessment to test your knowledge and earn CME credits.

 

Clinical takeaways

 

  • Heparins and/or DOACs are safe and efficient in treating thrombosis in cancer patients

  • Primary thromboprophylaxis is efficient in selected cancer patients but still remains a matter of debate for the majority of tumours

  • To improve quality of life, it is important to involve the patient in the treatment decision-making process

Prof. Dimitrios A. Tsakiris, MD was born in Thessaloniki, Greece and obtained his Diploma of Medicine (1982) at the Medical School, Aristotle University of Thessaloniki, Greece. He started his training in Clinical Haematology at the AHEPA University Hospital in Thessaloniki and completed it at the University Hospital Basel in Basel, Switzerland, where he has been working since 1987. He holds a license for Clinical Haematology and Laboratory Haematology. He spent one year (1996) as a Research Associate in Platelet Research at the Mount Sinai School of Medicine, New York, NY, USA. He has held a professorship in Haematology at the Faculty of Medicine, University of Basel, Switzerland since 2004 and serves also as a visiting Professor of Hematology at the Medical School of the Aristotle University of Thessaloniki. He has served as Head of Haemostasis since 2009 and Head of Diagnostic Haematology and Haemostasis (2014-2021), as well as member of the Stem Cell Transplant and Cell-Therapy Center Basel at the University Hospital Basel, Switzerland. Since 2021 he has been Director of Thrombosis and Haemostasis and Co-Head Hematology at SYNLAB Suisse SA, Switzerland. His main fields of scientific interests are platelet activation, platelet disorders, diagnosis and treatment of bleeding disorders and thrombophilia, disorders of haemostasis and endothelial cells after stem cell transplants. He has presented over 140 peer-reviewed original articles and reviews.

Dr Lars Asmis is Director at the Centre for Perioperative Thrombosis and Haemostasis in Zurich, Switzerland.  He completed his medical training at the University of Bern and has subsequently held positions at Inselspital Bern, University of Geneva and USZ Zurich.  In 2002 he worked as a visiting scientist at Johns Hopkins University in Baltimore, USA.  Dr Asmis has held a number of leadership positions including Co-president of the Swiss Working Party for Hemostasis from 2020 to 2021.  He has authored more than 50 peer-reviewed publications.

Dr Lars Asmis has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Viatris

Programme summary
Listen to the podcast now
Other episodes in this series
Monitoring Anticoagulation: Yes or No?

Monitoring Anticoagulation: Yes or No?

A clinical discussion on anticoagulation monitoring

Cancer and Thrombosis

Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Current Episode
VTE: What is the optimal duration of antithrombotic treatment?

VTE: What is the optimal duration of antithrombotic treatment?

Part 3 of a 4-part series on thrombosis

Perioperative thromboprophylaxis revisited

Perioperative thromboprophylaxis revisited

Minimising the risk of thrombosis in surgical patients

Share this programme
This educational programme is supported by an Independent Educational Grant from Viatris.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HEMOSTASIS CONNECT

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Pfizer, Takeda, Viatris and Pentapharm.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast

Episode

3

of 3

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Assoc. Prof. Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer

An expert overview of the EMERALD subgroup analysis

Experts
Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)

Managing patients with nccRCC: guidelines, recommendations, and best practice

Experts
Prof. Laurence Albiges
Endorsed by
Urobel VZW | ASBL
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
micro-learning Micro learning
Oncology 
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Risk factors, diagnostic tools and treatment options for different patient groups

Experts
Prof. Efrat Dotan, Prof. Shubham Pant
Endorsed by
Digestive Cancers Europe
PanCAN Let's win PC
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Ipsen USA.